Resultados da pesquisa - Dana E. Rathkopf

Refinar resultados
  1. 1
    Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer

    Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer Por Dana E. Rathkopf, Howard I. Scher

    Publicado em 2013
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Apalutamide for the treatment of prostate cancer

    Apalutamide for the treatment of prostate cancer Por Dana E. Rathkopf, Howard I. Scher

    Publicado em 2018
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Treatment of Advanced Prostate Cancer

    Treatment of Advanced Prostate Cancer Por Min Yuen Teo, Dana E. Rathkopf, Philip W. Kantoff

    Publicado em 2019
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  4. 4
    Treating the patient and not just the cancer: therapeutic burden in prostate cancer

    Treating the patient and not just the cancer: therapeutic burden in prostate cancer Por Daniel E. Spratt, Neal D. Shore, Oliver Sartor, Dana E. Rathkopf, Kara Olivier

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  5. 5
    Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

    Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) Por Deborah Bradley, Dana E. Rathkopf, Rodney L. Dunn, Walter M. Stadler, Glenn Liu, David C. Smith, Роберто Пили, James A. Zwiebel, Howard I. Scher, Maha Hussain

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

    A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer Por Dana E. Rathkopf, Joel Picus, Arif Hussain, Susan Ellard, Kim Nguyen, Thomas Nydam, E. Allen-Freda, Kaushal Mishra, Maria Grazia Porro, Howard I. Scher, George Wilding

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

    Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors Por Monica Fornier, Dana E. Rathkopf, Manisha H. Shah, S. Patil, Eileen M. O’Reilly, Archie Tse, C. Hudis, Robert A. Lefkowitz, David P. Kelsen, Gary K. Schwartz

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer

    Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer Por Matthew R. Smith, Dana E. Rathkopf, Peter F.A. Mulders, Joan Carles, Hendrik Van Poppel, Jinhui Li, Thian Kheoh, Thomas W. Griffin, Arturo Molina, Charles J. Ryan

    Publicado em 2015
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

    A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer Por Laura Graham, Kalyan Banda, Alba Torres, Brett S. Carver, Yu Chen, Katie Pisano, Greg Shelkey, Tracy Curley, Howard I. Scher, Tamara L. Lotan, Andrew C. Hsieh, Dana E. Rathkopf

    Publicado em 2018
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide

    Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide Por Alexander Pan, Rachel Reingold, Jimmy L. Zhao, Andrea P. Moy, Lukas Kraehenbuehl, George Dranitsaris, Sean M. McBride, Howard I. Scher, Marisa Kollmeier, Han Xiao, Dana E. Rathkopf, Mario E. Lacouture

    Publicado em 2022
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer

    Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer Por Dana E. Rathkopf, Tomasz M. Beer, Yohann Loriot, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. de Bono, Bertrand Tombal, Teresa Parli, Suman Bhattacharya, De Phung, Andrew Krivoshik, Howard I. Scher, Michael J. Morris

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics

    Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics Por Bastien Nguyen, José Maurício Mota, Subhiksha Nandakumar, Konrad H. Stopsack, Emily S. Weg, Dana E. Rathkopf, Michael J. Morris, Howard I. Scher, Philip W. Kantoff, Anuradha Gopalan, Dmitriy Zamarin, David B. Solit, Nikolaus Schultz, Wassim Abida

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

    Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Can... Por Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan, William L. Berry, Neal D. Shore, Glenn Liu, Joshi J. Alumkal, Celestia S. Higano, Edna Chow Maneval, Rajesh Bandekar, Carla J. de Boer, Margaret K. Yu, Dana E. Rathkopf

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

    Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer Por Jorge A. Carrasquillo, Joseph A. O’Donoghue, Neeta Pandit‐Taskar, John L. Humm, Dana E. Rathkopf, Susan F. Slovin, Matthew J. Williamson, Kristine Peregrino Lacuna, Anne-Kirsti Aksnes, Steven M. Larson, Howard I. Scher, Michael J. Morris

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

    Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer Por Emmanuel S. Antonarakis, Elisabeth I. Heath, David C. Smith, Dana E. Rathkopf, Amanda L. Blackford, Daniel C. Danila, Serina King, Anja S. Frost, A. Seun Ajiboye, Ming Zhao, Janet Mendonca, Sushant K. Kachhap, Michelle A. Rudek, Michael A. Carducci

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone

    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone Por Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla J. de Boer, Margaret K. Yu, Howard I. Scher

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer

    First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can... Por Diletta Bianchini, Aurelius Omlin, Carmel Pezaro, David Lorente, Roberta Ferraldeschi, Deborah Mukherji, Mateus Crespo, I. Figueiredo, Susana Miranda, Ruth Riisnaes, Andrea Zivi, Aby Buchbinder, Dana E. Rathkopf, Gerhardt Attard, Howard I. Scher, Johann S. de Bono, Daniel C. Danila

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

    Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL Por Alan H. Bryce, Joshi J. Alumkal, Andrew J. Armstrong, Celestia S. Higano, Peter Iversen, Cora N. Sternberg, Dana E. Rathkopf, Yohann Loriot, Johann S. de Bono, Bertrand Tombal, Sarang Abhyankar, Po‐Han Lin, Andrew Krivoshik, D. Phung, Tomasz M. Beer

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

    Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer Por Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Daniel C. Danila, Susan F. Slovin, Jeffrey H. Hager, Peter J. Rix, Edna Chow Maneval, Isan Chen, Mithat Gönen, Martin Fleisher, Steven M. Larson, Charles L. Sawyers, Howard I. Scher

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

    Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 Por Johann S. de Bono, Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric J. Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian Kheoh, Jinhui Li, Mary B. Todd, Charles J. Ryan, Thomas W. Flaig

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: